Vermillion, Quest Ink Deal to Sell OVA1 in India

Apr 04, 2011

NEW YORK (GenomeWeb News) – Vermillion today announced an agreement with Quest Diagnostics for the launch of the OVA1 ovarian cancer test in India.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in PNAS

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

Leaving It All Over Town

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

Balance of Research and Privacy

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

What We'd Do With the Money

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

Featured White Papers

Reducing the variability of pre-analytical handling of biological samples

Main menu